← back to search

Chadi Nabhan

Deerfield (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Prostate Cancer Treatment and Research, PARP inhibition in cancer therapy, Cancer Immunotherapy and Biomarkers, and Cancer Genomics and Diagnostics.
h-index
25
citations
2,378
works
280
NIH funding
primary concept
email

Recent publications

Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Cancer Immunology Research 2025cited by 10position: middledoi
Structurally Oriented Classification of <i>FOXA1</i> Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Clinical Cancer Research 2025cited by 10position: middledoi
Pan-Cancer Interrogation of B7-H3 ( <i>CD276</i> ) as an Actionable Therapeutic Target Across Human Malignancies
Cancer Research Communications 2024cited by 20position: middledoi
Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type
Translational Oncology 2021cited by 47position: middledoi
Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes
Cancers 2021cited by 29position: middledoi
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
Journal of Clinical Oncology 2021cited by 14position: middledoi
Use of class I histone deacetylase inhibitor romidepsin in combination regimens
Leukemia & lymphoma/Leukemia and lymphoma 2016cited by 40position: lastdoi
Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma
Cancer 2015cited by 85position: lastdoi
Prostate Cancer Screening
JAMA 2015cited by 37position: lastdoi
A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
British Journal of Cancer 2013cited by 56position: lastdoi
Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study
Clinical Genitourinary Cancer 2013cited by 21position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Joanne Xiu · Enzo Life Sciences (United States)4 papers (2021–2025)Elisabeth I. Heath · Mayo Clinic4 papers (2021–2025)W. Michael Korn · Itasca Community College3 papers (2021–2021)Rana R. McKay · The Barbara Ann Karmanos Cancer Institute3 papers (2024–2025)Milan Radovich · Caris Life Sciences (United States)2 papers (2024–2025) · 2 papers (2025–2025)Adam M. Petrich · AbbVie (United States)2 papers (2015–2016) · 2 papers (2013–2013)Scott M. Dehm · University of Minnesota2 papers (2024–2025)Oliver Sartor · Tulane University2 papers (2024–2025)Julie McGrath · University of Arizona2 papers (2021–2021)Chukwuemeka Ikpeazu · Sylvester Comprehensive Cancer Center2 papers (2021–2021)Justin H. Hwang · University of Minnesota2 papers (2024–2025) · 2 papers (2025–2025) · 2 papers (2013–2013)Jacob J. Orme · The University of Texas Southwestern Medical Center2 papers (2024–2025)Emmanuel S. Antonarakis · University of Minnesota2 papers (2024–2025)Andrew Elliott · Intel (United States)2 papers (2024–2025)Amber N. Clements · University of Arizona1 papers (2025–2025)Carly D. Miller · University of California System1 papers (2024–2024)